Search

Smith & Nephew PLC

Fermé

1,225 -0.65

Résumé

Variation du prix de l'action

24h

Actuel

Min

1215.5

Max

1234

Chiffres clés

By Trading Economics

Revenu

296M

Ventes

3B

P/E

Moyenne du Secteur

28.81

23.145

BPA

0.429

Rendement du dividende

3.08

Marge bénéficiaire

9.895

Employés

17,000

EBITDA

723M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+18.62% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.08%

4.30%

Prochains Résultats

2 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.3B

10B

Ouverture précédente

1225.65

Clôture précédente

1225

Smith & Nephew PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 janv. 2026, 21:55 UTC

Résultats

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 janv. 2026, 23:52 UTC

Résultats

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 janv. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 janv. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 janv. 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 janv. 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 janv. 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 janv. 2026, 22:37 UTC

Market Talk
Acquisitions, Fusions, Rachats

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 janv. 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

22 janv. 2026, 21:44 UTC

Résultats

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 janv. 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 janv. 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 janv. 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 janv. 2026, 21:30 UTC

Résultats

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Capital One To Acquire Brex >COF

22 janv. 2026, 21:13 UTC

Résultats

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 janv. 2026, 21:11 UTC

Résultats

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 janv. 2026, 21:11 UTC

Résultats

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 janv. 2026, 21:10 UTC

Résultats

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 janv. 2026, 21:06 UTC

Résultats

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Rev $15.58B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q EPS $3.26 >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net Interest Margin 8.26% >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net $2.13B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Adj EPS $3.86 >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net Charge-Offs $3.8B >COF

22 janv. 2026, 21:05 UTC

Résultats

Intuitive Surgical 4Q EPS $2.21 >ISRG

Smith & Nephew PLC prévision

Objectif de Prix

By TipRanks

18.62% hausse

Prévisions sur 12 Mois

Moyen 1,465.5 GBX  18.62%

Haut 1,650 GBX

Bas 1,290 GBX

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

5

Achat

3

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat